Equity Overview
Price & Market Data
Price: $10.64
Daily Change: +$0.08 / 0.75%
Daily Range: $10.35 - $10.95
Market Cap: $1,364,368,640
Daily Volume: 1,420,539
Performance Metrics
1 Week: -2.74%
1 Month: 3.30%
3 Months: -5.92%
6 Months: 43.40%
1 Year: 121.7%
YTD: -15.02%
Company Details
Employees: 26
Sector: Health technology
Industry: Biotechnology
Country:
Details
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis. Trevi Therapeutics, Inc. has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.